Effectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study

Effectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 30; pp. v139 - v140
Main Authors: Alés-Martínez, J.E., Morales, S., Fernández Abad, M., Sánchez-Rovira, P., Salvador Bofill, F.J., Lahuerta, A., García-Sáenz, J.A., Garau Llinas, I., Díaz Redondo, T., Ferrer, N., Carañana, V., López, R., Alonso Soler, S.E., Bermejo, B., de la Haba, J., Zamora, P., Balmana, J., López-Miranda, E., Cortés, J., Llombart Cussac, A.
Format: Journal Article
Language:English
Published: 01-10-2019
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
DOI:10.1093/annonc/mdz242.079